Aimmune's Peanut Immunotherapy Palforzia Gets CHMP Backing
Company Bought By Nestlé Health Science Days Earlier
Palforzia will almost certainly be the first treatment to get the green light for peanut allergy in Europe and its new owner will be hoping for a more successful launch than has been seen in the US.
You may also be interested in...
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.
Two biotech start-up studios have been launched to nurture new ventures in the microbiome and synthetic biology fields, with cash already gone into three of them: Omne Possibile, Stellate Therapeutics and NovoBiome.
Having been given a PDUFA target date of 1 January, 2022, Strongbridge is already preparing for a happy new year challenging Recordati's Isturisa for market share in the Cushing's syndrome space